Show simple item record

dc.contributor.authorMcGuinness, Jonathan
dc.contributor.authorNeilan, Tom G
dc.contributor.authorCummins, Rob
dc.contributor.authorSharkasi, Adel
dc.contributor.authorBouchier-Hayes, David
dc.contributor.authorRedmond, J Mark
dc.date.accessioned2011-04-07T10:59:14Z
dc.date.available2011-04-07T10:59:14Z
dc.date.issued2009-03
dc.identifier.citationIntravenous glutamine enhances COX-2 activity giving cardioprotection. 2009, 152 (1):140-7 J. Surg. Res.en
dc.identifier.issn1095-8673
dc.identifier.pmid18708191
dc.identifier.doi10.1016/j.jss.2008.03.045
dc.identifier.urihttp://hdl.handle.net/10147/127682
dc.description.abstractPreconditioning, a highly evolutionary conserved endogenous protective response, provides the most powerful form of anti-infarct protection known. We investigated whether acute intravenous glutamine, through an effect on cyclooxygenase (COX)-2 and heat shock protein (HSP) 72, might induce preconditioning.
dc.description.abstractMale New Zealand white rabbits (n = 28) received either 0.5 g/kg glutamine in 0.9% saline or saline only in divided doses for 3 d. The large marginal branch of the left coronary was occluded for 30 min; cardiac function was assessed during 3 h of reperfusion, and infarct size was measured. 6-Keto-PGF-1alpha, nitrate, and malonaldehyde serum levels were determined. Hearts were taken from a further group of pretreated rabbits (n = 10) to assess myocardial COX-2 and HSP72 levels.
dc.description.abstractGlutamine pretreatment resulted in a 39% reduction in infarct size (30.7 +/- 2.0% versus 50.4 +/- 2.1% controls; P < 0.01). Myocardial COX-2 levels were significantly elevated with pretreatment (P < 0.05) and were mirrored by higher serum 6-keto-PGF-1alpha levels prior to ischemia (69 +/- 13 versus 18 +/- 21 pg/mL in controls, P = 0.027). There was no significant difference in myocardial HSP72 or serum nitrate levels following pretreatment, or malonaldehyde levels during reperfusion.
dc.description.abstractGlutamine pretreatment confers anti-infarct protection through up-regulation of COX-2, a key mediator of delayed preconditioning protection. Previous confirmation of its clinical safety profile at these doses suggests an acceptable strategy for inducing preconditioning for perioperative protection.
dc.language.isoenen
dc.subject.mesh6-Ketoprostaglandin F1 alpha
dc.subject.meshAnimals
dc.subject.meshCyclooxygenase 2
dc.subject.meshGlutamine
dc.subject.meshHSP72 Heat-Shock Proteins
dc.subject.meshHemodynamics
dc.subject.meshInjections, Intravenous
dc.subject.meshIschemic Preconditioning, Myocardial
dc.subject.meshMale
dc.subject.meshMalondialdehyde
dc.subject.meshMyocardial Reperfusion Injury
dc.subject.meshMyocardium
dc.subject.meshNitrates
dc.subject.meshRabbits
dc.titleIntravenous glutamine enhances COX-2 activity giving cardioprotection.en
dc.typeArticleen
dc.contributor.departmentThe Royal College of Surgeons in Ireland, Department of Surgery, Beaumont Hospital, Dublin, Ireland.en
dc.identifier.journalThe Journal of surgical researchen
dc.description.provinceLeinster
html.description.abstractPreconditioning, a highly evolutionary conserved endogenous protective response, provides the most powerful form of anti-infarct protection known. We investigated whether acute intravenous glutamine, through an effect on cyclooxygenase (COX)-2 and heat shock protein (HSP) 72, might induce preconditioning.
html.description.abstractMale New Zealand white rabbits (n = 28) received either 0.5 g/kg glutamine in 0.9% saline or saline only in divided doses for 3 d. The large marginal branch of the left coronary was occluded for 30 min; cardiac function was assessed during 3 h of reperfusion, and infarct size was measured. 6-Keto-PGF-1alpha, nitrate, and malonaldehyde serum levels were determined. Hearts were taken from a further group of pretreated rabbits (n = 10) to assess myocardial COX-2 and HSP72 levels.
html.description.abstractGlutamine pretreatment resulted in a 39% reduction in infarct size (30.7 +/- 2.0% versus 50.4 +/- 2.1% controls; P < 0.01). Myocardial COX-2 levels were significantly elevated with pretreatment (P < 0.05) and were mirrored by higher serum 6-keto-PGF-1alpha levels prior to ischemia (69 +/- 13 versus 18 +/- 21 pg/mL in controls, P = 0.027). There was no significant difference in myocardial HSP72 or serum nitrate levels following pretreatment, or malonaldehyde levels during reperfusion.
html.description.abstractGlutamine pretreatment confers anti-infarct protection through up-regulation of COX-2, a key mediator of delayed preconditioning protection. Previous confirmation of its clinical safety profile at these doses suggests an acceptable strategy for inducing preconditioning for perioperative protection.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record